Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An epithelioid sarcoma occurring in adults.
Biomarker and diagnostic research for adult epithelioid sarcoma has been reported in the published literature.
12 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 6 PHASE2, 4 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03967834](https://clinicaltrials.gov/study/NCT03967834) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 8:50 PM UTC
Common questions about adult epithelioid sarcoma
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group |
NA |
Institut Claudius Regaud |
RECRUITING |
[NCT07089992](https://clinicaltrials.gov/study/NCT07089992) | A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | PHASE2 | Memorial Sloan Kettering Cancer Center | RECRUITING |
[NCT06625190](https://clinicaltrials.gov/study/NCT06625190) | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | PHASE1 | University of Florida | RECRUITING |
[NCT06277154](https://clinicaltrials.gov/study/NCT06277154) | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | PHASE2 | HRYZ Biotech Co. | RECRUITING |
[NCT04390737](https://clinicaltrials.gov/study/NCT04390737) | Evaluate the Safety and Clinical Activity of HH2853 | PHASE1 | Haihe Biopharma Co., Ltd. | RECRUITING |
279 publications have been identified in PubMed for adult epithelioid sarcoma. Kisho has analyzed 78 by research type. Research spans Case Report / Case Series (23%), Epidemiology / Natural History (21%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 18 | 23% |
Disease patterns and progression | 16 | 21% |
Clinical study results | 13 | 17% |
Research summaries | 11 | 14% |
Laboratory research | 11 | 14% |
Testing and diagnosis research | 8 | 10% |
New treatment approaches | 1 | 1% |
Fanburg-Smith JC (2026). [PMID: 41455220](https://pubmed.ncbi.nlm.nih.gov/41455220/). *Semin Diagn Pathol*. [Review / Meta-Analysis]
Bansal A (2026). [PMID: 41500705](https://pubmed.ncbi.nlm.nih.gov/41500705/). *BMJ Case Rep*. [Case Report / Case Series]
Rodriguez-Hernandez A (2026). [PMID: 41092038](https://pubmed.ncbi.nlm.nih.gov/41092038/). *J Natl Cancer Inst*. [Clinical Trial Publication]
Halberg Dybdal DT (2026). [PMID: 42017353](https://pubmed.ncbi.nlm.nih.gov/42017353/). *Acta Oncol*. [Epidemiology / Natural History]
Trama A (2025). [PMID: 39848113](https://pubmed.ncbi.nlm.nih.gov/39848113/). *Eur J Cancer*. [Epidemiology / Natural History]
Santolia CB (2025). [PMID: 40973350](https://pubmed.ncbi.nlm.nih.gov/40973350/). *JACC Case Rep*. [Case Report / Case Series]
Dundr P (2025). [PMID: 39921027](https://pubmed.ncbi.nlm.nih.gov/39921027/). *Lab Invest*. [Basic Science / Preclinical]
Fernández-Pérez J (2025). [PMID: 40513989](https://pubmed.ncbi.nlm.nih.gov/40513989/). *Mod Pathol*. [Basic Science / Preclinical]
Akhtar S (2025). [PMID: 40907264](https://pubmed.ncbi.nlm.nih.gov/40907264/). *Rev Esp Patol*. [Review / Meta-Analysis]
Sigalotti L (2025). [PMID: 39491746](https://pubmed.ncbi.nlm.nih.gov/39491746/). *Mod Pathol*. [Basic Science / Preclinical]
AI-curated news mentioning adult epithelioid sarcoma
Updated Mar 24, 2026
New research highlights the therapeutic vulnerabilities associated with SMARCB1 loss in epithelioid sarcoma. This study provides insights that could inform future treatment strategies for this rare cancer.
Ipsen withdraws Tazverik from the market for follicular lymphoma and epithelioid sarcoma due to emerging data indicating an increased risk of secondary malignancies. This decision impacts ongoing treatment options for patients with these cancers.